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Abstract: Clean surgery without contamination does not require prophylactic antibiotics, but there 
are high-risk surgical procedures that may cause infection and/or involve vital organs such as the 
heart, brain, and lungs, and these indeed require the use of antibiotics. This study aimed to deter-
mine the quantity of antibiotic use based on the defined daily dose (DDD) per 100 bed days and the 
quality of antibiotic use based on the percentage of concordance with The American Society of 
Health-System Pharmacists (ASHP) therapeutic guidelines (i.e., route of administration, time of ad-
ministration, selection, dose, and duration). This includes the profiles of surgical site infection (SSI) 
in surgical patients from January through June 2019. The study subjects were 487 surgical patients 
from two hospitals who met the inclusion criteria. There were 322 patients out of 487 patients who 
had a clean surgical procedure. Ceftriaxone (J01DD04) was the most used antibiotic, with a total 
DDD/100 bed days value in hospitals A and B, respectively: pre-surgery: 14.71, 77.65, during sur-
gery: 22.57, 87.31, and postsurgery: 38.34, 93.65. In addition, 35% of antibiotics were given more 
than 120 min before incision. The lowest concordance to ASHP therapeutic guideline in hospital A 
(17.6%) and B (1.9%) was antibiotic selection. Two patients experienced SSI with bacterial growths 
of Proteus spp., Staphylococcus aureus, Staphylococcus epidermidis, and Escherichia coli. The usage of 
prophylactic antibiotics for surgical procedures was high and varied between hospitals. Hospital B 
had significantly lower concordance to antibiotic therapeutic guidelines, resulting to a higher infec-
tion rate, compared with hospital A. ASHP adherence components were then further investigated, 
after which antibiotic dosing interval and injection time was found to be a significant predictor for 
positive bacterial growth based on logit–logistic regression. Further interventions and strategies to 
implement antibiotic stewardship is needed to improve antibiotic prescriptions and their use. 
Keywords: defined daily dose; surgical site infection; antibiotic stewardship; hospital 
 
1. Introduction 
Antimicrobial resistance threatens global health; antibiotic use in surgical specialties 
is an infection control indicator and may reflect the incidence of surgical site infection. In 
most developing countries, particularly Indonesia, antibiotics are given before the inci-
sion but also during the time from admission to discharge from the hospital which may 
result in higher chances of antimicrobial resistance. A new strategy is therefore needed to 
overcome this problem. 
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Surgery is a medical procedure in the form of an incision made by a surgeon with the 
aim of preventing or treating an illness. In general, all surgical procedures can pose a risk 
of infection. Thus, antibiotic prophylaxis is needed to prevent postoperative infection. 
However, not all types of surgery require antibiotic prophylaxis. Clean surgery without 
contamination does not require prophylactic antibiotics unless there are high-risk proce-
dures that may cause infection and/or involve vital organs such as the heart, brain, and 
lungs. Prophylactic antibiotics are generally recommended in some clean and all contam-
inated operations [1]. In general, the use of antibiotic prophylaxis must be in accordance 
with therapeutic standards. However, the percentage compliance with guidelines for an-
tibiotic use (e.g., NICE Guidelines, Stanford Health Care Guidelines, Surgical Antimicro-
bial Prophylaxis Guidelines) is relatively low (under 50%) in several countries such as 
Qatar (46.5%), Pakistan (< 50%), Italy (40%), and the Philippines (13%) [2]. 
The mismatch of antibiotic use with therapeutic guidelines is reported to be high in 
surgical ward [3], ICU [3,4], and medical ward [3] with mismatches to the indication, an-
tibiotic selection [3,4], and time/dose/route/duration of antibiotic administration. Often, 
differences existed from the internal guidelines [3] especially in prescribing prophylactic 
antibiotics pre- and postsurgery. A study showed that in pre-surgery, 46% incorrect tim-
ing, 32% incorrect dosages, and 20% overly broad antibiotic spectrum were reported; 
while in postsurgery, they found 74% incorrect duration of antibiotic administration, 29% 
incorrect dosage or frequency, and 6% overly broad spectrum of antibiotics [5]. 
Prescribing antibiotics preoperatively can reduce the occurrence of wound infection. 
Whereas not following the guidelines, for example, by using different spectrum antibiot-
ics or different tissue antibiotic concentrations at the start and during surgery, can reduce 
antibiotics’ effectiveness. Moreover, antibiotic selection pressure leads to antibiotic re-
sistance. The incidence of SSI is significantly higher when prophylactic antibiotics are 
given postsurgery than when given presurgery with an odds ratio (OR) of 1.89 (95% CI 
1.05–3.4). Prophylactic antibiotics more than 120 min preincision showed a higher preva-
lence of SSI than those within 120 min (OR 5.26; 95% CI (3.29–8.39)) [6–8]. The use of 
prophylactic antibiotics that are irrational or not in accordance with therapeutic guide-
lines requires preventive efforts so as not to cause cases of resistance to prophylactic anti-
biotics. According to the Indonesian National Action Plan for Antimicrobial Resistance 
2017–2019, one of the preventive efforts that can be conducted is to evaluate the use of 
prophylactic antibiotics in its quantity and quality. 
World Health Organization (2019) states that implementing antimicrobial steward-
ship by evaluating the use of antibiotics can optimize the use of antibiotics, encourage 
behavior change in prescribing antibiotics, improve quality of care and patient outcomes, 
save unnecessary health care costs, and reduce the emergence, selection, and further 
spread of antimicrobial resistance (AMR) [9–14]. A systematic review by Nathwani et al. 
(2019) of 146 studies in North America (49%), Europe (25%), Asia (14%), Africa (3%), South 
America (3%), and Australia (3%) reported a decrease in length of stay (LOS) and antibi-
otic expenditure, respectively, by 85 and 92%; mean cost savings in the US study were 
USD 732 per patient (range: USD 2.50 to 2640), with a similar trend shown in European 
studies [14]. Hence, taking into account the importance and positive outcome of antibiot-
ics stewardship, this study aimed to evaluate the quantity (DDD/100 bed-days) and qual-
ity of prophylactic antibiotic use in surgical patients in hospitals while assessing the im-
pact of concordance towards ASHP therapeutic guideline towards the risk of SSI. 
2. Materials and Methods 
2.1. Study Design 
A retrospective observational study in both hospitals was conducted by observing 
patients who underwent surgical procedures during hospitalization at a private hospital 
in Surabaya (hospital A) and West Nusa Tenggara (hospital B) in the period January–June 
2019. Hospital A is a private hospital with 235 beds, whereas hospital B is a government 
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hospital with 411 beds. Both hospitals are referral hospitals. Surgical procedures classifi-
cations were (1) clean surgery—surgery performed on an area without preoperative in-
fection and without opening the tract (respiratory, gastrointestinal, urinary, biliary), 
planned surgery, or primary skin closure with or without the use of closed drains, (2) 
clean-contaminated operations—operations performed on the ducts (gastrointestinal, bil-
iary, urinary, respiratory, and reproductive except ovaries) or operations without signifi-
cant contamination, and (3) contaminated surgery—surgery that opened the digestive 
tract, bile duct, urinary tract, airway to the oropharynx, or reproductive tract except for 
ovaries with gross spillage [6]. 
Inclusion criteria included patients aged >18 years old who received prophylactic an-
tibiotics, underwent surgery, and hospitalization in the surgical ward, including surgical 
wound control within <90 days postoperatively. The exclusion patient criteria were pa-
tients in the intensive care unit (ICU), patients who had an infection before surgery, those 
discharged “against medical advice” (AMA), and those who died. 
Slovin’s formula was used to calculate the appropriate sample size (n) from a popu-
lation using the known population size (N) and the acceptable error value (e). In this 
study, simple random sampling was used from the population of admitted patients in the 
study period; N = 267 participants, e = 0.05; therefore, n = 160 participants hospital A; N = 
1597 participants, e = 0.05; therefore, n = 320 participants hospital B. 
Slovin calculations used Equation (1) as follows: 
n =  
N
(1 + N ×  0.052)
 (1) 
Antibiotic usage data were obtained from patient medical records and antibiotic use 
records compiled by pharmaceutical software, which stores all patient data. Data were 
collected from inpatient medical records, including diagnosis, surgery, length of hospital-
ization, drug name, dose, and the number of antibiotics received. The dataset was anony-
mized prior to analysis. 
In Indonesia, antibiotics can be prescribed to the patient at admission, during patient 
care, until the patient’s discharge, and usually two weeks after discharge (next outpatient 
consultation). In this study, antibiotic use classifications were pre-, during, and postsur-
gery. Presurgery represents antibiotics given before the day of surgery; antibiotics during 
surgery are given on the day of surgery (120 min preincision to < 24 h after surgery), and 
antibiotics postsurgery are given > 24 h after surgery. 
The obtained data were evaluated for antibiotic uses quantitatively and qualitatively. 
The quantitative evaluation used DDD per 100 bed-days, while the qualitative analysis 
was the percentage of antibiotic concordance to the American Society of Health-System 
Pharmacists (ASHP) Therapy Guidelines in (1) route of administration, (2) time, (3) type, 
(4) dosage, and (5) duration. 
Data on bacterial culture test results were obtained from clinical pathology laborato-
ries, and prevention and control committees of infection to follow up regarding the bac-
teria that cause SSI in postsurgical patients. Patients with SSI were observed in the time 
they were in the hospital, and when they went to the doctor for review, until the patient 
was declared cured. 
2.2. Statistical Analysis 
All patient data were anonymized prior to analysis. Data analysis was performed 
descriptively in the form of an analysis of the quantity of prophylactic antibiotic use with 
the DDD/100 bed-days, which was calculated using the following formula: 
DDD
100
bed − days =  
Total Antibiotics (g)  ×  100
DDD WHO (g)  ×  LOS
 (2) 
where DDD WHO = defined daily dose determined by WHO; LOS = total length of stay. 
Pharmaceuticals 2021, 14, 1088 4 of 11 
 
 
The percentage of compliance with guidelines of antibiotic use with the ASHP ther-
apeutic guidelines was analyzed using the 2014 SIGN criteria as a quality analysis, includ-
ing the sensitivity profile of the bacteria causing SSI. 
A generalized ANOVA model was also carried out on the aggregated DDD dataset 
to identify the overall difference between the two hospitals in this study. Z-test, in con-
junction with Monte Carlo simulation, was also used to investigate which hospital was 
most adhering to ASHP guidelines. In addition, logit–logistic regression was utilized in 
this study to further investigate which ASHP adherence components that would be the 
significant predictor for reported infection cases. Participants’ demographics (e.g., age, 
gender), comorbidities, and antibiotic usage were included as covariates in the model. 
3. Results 
A total of 487 patients in both hospitals met the inclusion and exclusion criteria. Table 
1 describes the demographic information of the patients in the study. Table 1 shows that 
268 patients (55%) were female, 298 patients (61%) were aged between 31 and 60 years 
old, 393 patients (81%) of patients with out-of-pocket payment, and 57 patients (12%) had 
comorbidities. Overall, 322 patients underwent surgery with a clean operation category 
(94 patients in hospital A, and 228 patients in hospital B) (Table 1); in 164 patients (34%), 
the injection time given was greater than 120 min (Table 2). 
Table 1. Demographics information. 
Characteristic Hospital A (N = 164) Hospital B (N = 323) Total (N = 487) 
Age (years) 
18–30 30 (18.3%) 59 (18.3%) 89 (18.3%) 
31–45 56 (34.1%) 95 (29.4%) 151 (31.0%) 
46–60 44 (26.8%) 103 (31.9%) 147 (30.2%) 
61–75 31 (18.9%) 66 (20.4%) 97 (19.9%) 
>75 3 (1.8%) 0 3 (0.6%) 
Gender 
Male 61 (37.2%) 158 (48.9%) 219 (45.0%) 
Female 103 (62.8%) 165 (51.1%) 268 (55.0%) 
Pay providers 
Out of pocket 85 (51.8%) 308 (95.4%) 393 (80.7%) 
National Health Insurance 79 (48.2%) 15 (4.6%) 94 (19.3%) 
Comorbidities 
Without comorbidities 117 (71.3%) 313 (96.9%) 430 (88.3%) 
With comorbidities * 47 (28.7%) 10 (3.1%) 57 (11.7%) 
Surgical procedure 
Clean 94 (57.3%) 228 (70.6%) 322 (66.1%) 
Clean contaminated 65 (39.6%) 95 (29.4%) 160 (32.9%) 
Contaminated ** 5 (3.0%) 0 5 (1.0%) 
* Comorbidities: diabetes mellitus (DM), hypertension, cardiovascular disease (CVD), gout, cere-
brovascular accident (CVA), and others. ** contaminated: an acute incision, nonpurulent drainage. 
Table 2. Antibiotic usage for both hospitals. 
Category Hospital A (N = 164) Hospital B (N = 323) Total (N = 487) 
The number item of antibiotic 
No antibiotic 15 (9.1%) 0 15 (3.1%) 
1 antibiotic 130 (79.3%) 323 (100%) 453 (93.0%) 
2 antibiotics 18 (11.0%) 0 18 (3.7%) 
>2 antibiotics 1 (0.6%) 0 1 (0.2%) 
Injection time given 
0–30 min 35 (21.3%) 57 (17.6%) 92 (18.9%) 
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31–60 min  32 (19.5%) 83 (25.7%) 115 (23.6%) 
61–120 min 55 (33.5%) 46 (14.2%) 101 (20.7%) 
>120 min 27 (16.5%) 137 (42.4%) 164 (33.7%) 
Record not available 15 (9.1%) 0 15 (3.1%) 
3.1. Quantity Profile of Prophylactic Antibiotics 
Pre-, During, and Postsurgeries 
Based on the recapitulation of antibiotic prophylaxis (DDD/100 bed-days) in hospi-
tals A and B, respectively, between January and June 2019, the antibiotic use prophylaxis 
presurgery was 44.26 and 133.58; during surgery was 33.32 and 132.4; postsurgery was 
66.65 and 148.68. Ceftriaxone had the highest DDD/100 patient days in the pre-, during, 
and postsurgery, with sequences of 14.71 and 77.65, 22.57 and 87.31, 38.34, and 93.65 (Ta-
ble 3). Overall, hospital B had significantly higher usage then hospital A (F(1,5) = 66.124, p 
< 0.001). 
Table 3. The DDD per 100 bed-days antibiotics use for surgical procedures. 
ATC * Code Antibiotic Name 
Pre- During Post- 
Hospital A Hospital B Hospital A Hospital B Hospital A Hospital B 
J01CA04 Amoxicillin - 7.93 - - 0.72 1.11 
J01CR01 Bactesyn a - - - 5.59 - - 
J01CR02 Clanexi b - - - - - 0.54 
J01DB04 Cefazolin 0.74 - 2.82 - 1.55 - 
J01DB05 Cefadroxil - 0.94 - - - 1.09 
J01DD01 Cefotaxime - 6.07 0.04 8.92 0.04 8.70 
J01DD02 Ceftazidime - 2.87 0.14 3.96 - 3.72 
J01DD04 Ceftriaxone 14.71 77.65 22.57 87.31 38.34 93.65 




12.26 0.67 3.06 0.62 10.17 0.79 
J01DE01 Cefepime 1.47 - 0.14 - 1.45 - 
J01DH02 Meropenem 14.34 - 1.59 - 4.94 - 
J01FF01 Clindamycin - - - - - 1.65 
J01GB03 Gentamicin - - - - 0.17 - 
J01MA02 Ciprofloxacin - - - - - 1.97 
J01MA12 Levofloxacin - 16.07 0.14 - 0.64 - 
J01MA14 Moxifloxacin - - - 23.51 - 3.03 
J01XA01 Vancomycin - 2.68 - 1.60 - 3.41 
J01XD01 Metronidazole 0.74 - 2.82 0.89 8.63 2.23 
Total  44.26 133.58 33.32 132.40 66.65 148.68 
* Anatomical therapeutic chemical; a—ampicillin and beta-lactamase inhibitor; b—amoxicillin and beta-lactamase inhibi-
tor. 
3.2. Quality Profiles of Prophylactic Antibiotics 
Other than the route of administration, compatibility with ASHP guidelines was less 
than 50%. Order from highest to lowest conformity, the concordance to the ASHP guide-
lines was route of administration, injection given time, dosage, dosing interval, and selec-
tion (Table 4). In general, hospital A was more compliant than hospital B. Logistic regres-
sion revealed that injection given time (X2(1,162) = 283.62; p < 0.001) and dosing interval 
(X2(1,162) = 4.165; p < 0.041) were significant predictors for infection cases in hospital B. 
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Table 4. The percentage concordance to ASHP Therapeutic Guidelines. 
Concordance Type  Hospital A Hospital B z-Test (Monte Carlo) 
Antibiotic route of administration 96.6 100.0 z = −0.034; p < 0.05 
Antibiotic injection given time 53.4 42.7 z = 2.211; p < 0.05 
Antibiotic selection 17.6 1.9 z = 4.966; p < 0.001 
Antibiotic dosage 16.4 46.7 z = −7.445; p < 0.001 
Antibiotic dosing interval 19.1 19.2 z = 0.000; p = 1.0 
3.3. Profile of Surgical Site Infection (SSI) 
Surgical site infection occurs related to surgical incision procedures within 90 days 
of follow-up. Only two patients experienced SSI in this study. Both patients experiencing 
postoperative SSI were identified after undergoing a third review in the first patient, and 
after the first review in the second patient. The results of the first patient’s pus culture 
showed the presence of Proteus spp. and S. aureus, while the second patient had E. coli and 
S. epidermidis. Profiles of the types of bacteria that cause SSI are shown in Table 5. Both SSI 
patients were known to have had a history of diabetes mellitus, with a random blood 
sugar level of < 200 mg/dL while in the hospital, LOS preoperatively for >1 day, undergo-
ing surgery with a duration of operation > 60 min. The first SSI patient did not receive 
presurgical antibiotics, while the second patient received 2 × 1 g of ceftriaxone preopera-
tive antibiotics for 1 day. Both SSI patients received the same prophylactic antibiotic, i.e., 
ceftriaxone 2 × 1 g with the administration time > 120 min, and both dosages were contin-
ued until 4–5 days after incision. Neither received antibiotics when they were discharged. 
Table 5. The incidence of surgical site infection. 
Category Hospital A Hospital B 
Patients who return for control and cul-
ture 
0 4 
Patients with positive bacteria culture 
result 
0 2 
The bacteria culture result - 
Patient 1: Proteus sp. dan S. aureus 
Patient 2: E. coli dan S. epidermidis 
3.4. Bacteria Sensitivity Profile Causes SSI 
The results of antibiotic sensitivity tests showed that Escherichia coli bacteria are still 
sensitive to several types of antibiotics, such as cefoxitin, chloramphenicol, fosfomycin, 
oxacillin, tetracycline, and vancomycin. Bacteria Proteus spp. were sensitive to antibiotics 
such as amoxicillin, amoxicillin–clavulanate, ampicillin, ciprofloxacin, cotrimoxazole, 
fosfomycin, norfloxacin, ofloxacin. Proteus spp. and had intermediate sensitivity to cefox-
itin and chloramphenicol. Staphylococcus aureus bacteria were sensitive to chlorampheni-
col, oxacillin, and vancomycin and had intermediate sensitivity to amoxicillin, amoxicil-
lin–clavulanate, and cefoxitin. 
4. Discussion 
4.1. Quantity Profiles of Prophylactic Antibiotics 
The assessment of the quantity of antibiotic use was conducted by calculating 
DDD/100 bed-days based on the classification (Anatomical Therapeutic Chemical Classi-
fication) that has been approved worldwide by the World Health Organization (WHO). 
DDD is defined as the use of antibiotics based on the average daily dose given to 70 kgs 
adult patients according to main therapeutic indications. However, DDD cannot provide 
information pertaining to the suitability of the actual daily dose prescription. DDD calcu-
lation is influenced by the amount of antibiotic use (grams) and the total length of stay 
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(bed-days). The higher percentage of antibiotics use leads to the greater the DDD value 
[15]. 
The calculation of DDD/100 bed-days between January and June 2019 was divided 
into pre-, during, and postsurgeries. Overall, the average of prophylactic antibiotic use in 
pre, during, and postsurgeries in hospital B was higher than in hospital A. Ceftriaxone is 
the most widely used antibiotic including surgery. Tolbert’s 2019 evaluative study on the 
use of ceftriaxone in tertiary hospitals in Tanzania showed 322 (51.1%) of 630 research 
samples used ceftriaxone antibiotics. A total of 44 samples (40.7%) received ceftriaxone 
for surgical prophylaxis purposes that were divided into 32 (72.7%) samples receiving 
antibiotics before surgery, 3 samples (6.8%) samples receiving ceftriaxone antibiotics dur-
ing surgery, and 9 samples (20.5%) receiving antibiotics after surgery [16]. Another eval-
uative study on the use of prophylactic antibiotics in surgical patients at Nekemte Hospi-
tal Ethiopia showed that the 153 ceftriaxone samples were the most widely used antibiot-
ics, with a total of 66 samples (43.1%) [17]. 
Prophylactic antibiotics can significantly reduce the risk of postoperative infections. 
A meta-analysis of 40 studies testing the effectiveness of ceftriaxone compared with the 
comparators as the surgical prophylaxis (ampicillin–sulbactam, benzylpenicillin, 
cefamandole, cefazolin, cefotaxime, cefuroxime) showed that in clean operations, the in-
cidence of SSI in ceftriaxone was 5.14%, and comparator 6.2% (OR −0.22, 95% CI −0.51 to 
0.01; p = 0.047). In clean-contaminated operations, the incidence of SSI in ceftriaxone was 
4.6% and comparator 6.4% (OR −0.36, 95% CI −0.67 to −0.13; p = 0.001) [18].  
The average value of DDD/100 prophylactic antibiotic bed-days in this study is 
higher than other studies in one hospital in Indonesia but is still lower than that in the 
study of the use of prophylactic antibiotics in one hospital in Turkey. The ceftriaxone an-
tibiotics dosage used in hospital B was 87 DDD/100 bed-days, which means there were 87 
out of 100 patients who received ceftriaxone 1 DDD antibiotics per day. A primary study 
of surgical patients in the hospitals in Surabaya assessed the total use of ceftriaxone 
prophylactic antibiotics using the DDD/100 bed-days unit, and the total use of these anti-
biotics was 30–54 DDD/100 bed-days [19,20]. These results are still lower when compared 
with DDD/100 bed-days of this study. However, the total use of prophylactic antibiotics 
in this study was still lower than that in Turkey, which was 132.4 DDD/100 bed-days, 
compared with 289.32 DDD/100 bed-days [21]. 
4.2. Quality Profiles of Prophylactic Antibiotics 
According to Permenkes RI RI No. 2406/MENKES/PER/XII/2011 on General Guide-
lines for the Use of Antibiotics in 2011, the basis for selecting antibiotics should be drawn 
from the patterns of bacterial sensitivity to antibiotics, the clinical condition of patients, 
the selection priorities of first-line antibiotics or antibiotics with a narrow spectrum, cost, 
and adjusted according to the hospital diagnosis and therapy (PDT) Guidelines [11]. The 
results in this study indicated that of the 487 samples analyzed between January and June 
2019, the percentage of compliance with ASHP therapeutic guidelines for the selection of 
antibiotic types was 18% in hospital A and 2% in hospital B. We postulate that the low 
accordance in hospital B may be due to the fact that in Indonesia, antibiotics selection 
depends on the availability of the drugs rather than guideline recommendation.  
Based on ASHP therapeutic guidelines, to ensure adequate plasma and tissue con-
centration during surgery, it is recommended that the drug to be given intravenously 
within one hour of an incision. In this study, more than 95% of patients received prophy-
lactic antibiotics intravenously, but only around 50% in concordance with the preopera-
tive dosage timing recommendation. 
Some antibiotics, such as vancomycin and fluoroquinolones, must be given 120 min 
before surgery due to the influence of the half-life and protein binding of each antibiotic 
[22,23]. Allegranzi [7] conducted a meta-analysis of 13 observational studies on 53,975 
adult patients to assess the optimal time of administration of surgical prophylactic antibi-
otics and found that preoperative antibiotics are better than postsurgical drugs to prevent 
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surgical site infection (SSI) (OR 1.89; 95% CI 1.05–3.4). Administration of antibiotics earlier 
than 120 min showed a higher prevalence of SSI than the administration of antibiotics 
within 120 min (OR 5.26; 95% CI 3.29–8.39). 
The incidence of SSI in surgery patients in hospital B from January through June 2019 
was 2 out of 323 patients (0.62%). The SSI patients in this study both had ceftriaxone at 
intervals and doses of 2 × 1 g. The administration time was more than 2 h preincision. 
Mismatched timing of prophylactic antibiotics can cause SSI and the growth of resistant 
bacteria. Research conducted by Billoro in 2019 to evaluate the use of prophylactic antibi-
otics in 255 surgical patients in southern Ethiopia, using a prospective cohort study, 
showed that administration of surgical prophylactic antibiotics earlier than 1 h before the 
incision was associated with 20% of SSI cases, whereas administration within 1 h had a 
lower incidence, at 11.4% (p = 0.012). In addition, antibiotic resistance was observed in 
most types of bacteria in the surgical ward. One of these bacteria, Escherichia coli, was re-
sistant to the antibiotics such as ceftriaxone, chloramphenicol, ciprofloxacin, and gentami-
cin [24]. 
The selection of the right drug must be accompanied by an accurate dose determina-
tion. ASHP guidelines recommend ceftriaxone 2 g, or 50–75 mg/kg body weight, for adults 
[22,23]. The average body weight of the study sample was >40 kg; thus, the administration 
of <1 g of ceftriaxone injection was not in accordance with ASHP guidelines [25]. 
Aside from the timing of the first dose, the dosing interval and duration must be 
appropriate to achieve minimum effective plasma and tissue concentrations. ASHP rec-
ommends a single dose or that the duration of prophylactic antibiotics be <24 h postoper-
atively [23]. Using the case of more than 1000 beds hospital, Ayele’s 2017 evaluative study 
on the use of ceftriaxone in tertiary hospitals showed that around 70% use of antibiotic 
prophylaxis for a duration exceeding 7 days [26]. Limiting the duration of prophylactic 
antibiotics is crucial because the use of antibiotics with a longer duration has the potential 
to change the normal bacterial flora in the patient’s own body and the normal flora in the 
hospital environment. A disturbed flora can lead to colonization or antimicrobial re-
sistance [25]. The use of prophylactic antibiotics > 24 h carries the risk of increasing the 
incidence of acute kidney injury and infection by Clostridium difficile bacteria [27,28]. 
4.3. Profile of Surgical Site Infection (SSI) 
Extended preoperative waiting times for hospitalized patients increased the risks of 
SSI. Preoperative waiting time >7 days could increase the risk of SSI 2.48 times greater 
than preoperative waiting time <7 days (ARR = 2.48 (95% CI 1.28–4.79); p = 0.007) [24]. 
Both our infected patients underwent surgery after undergoing SSI > 7 days inpatient care. 
They also had a duration of operation > 1 h. Billoro (2019) found patients who underwent 
surgery >1 h were at risk of experiencing SSI 2.13 times higher than operations of <1 h 
(ARR = 2.13 (95% CI 1.18–3.86), p = 0.012) [24]. Gachabayov [29] found that the incidence 
of SSI was significantly higher in diabetic patients with hyperglycemia than nondiabetics 
ones with hyperglycemia (ARR = 2.10 (1.29–3.42, p = 0.002)). Our SSI patients were known 
to have a record of concomitant diabetes mellitus with preoperative blood sugar levels of 
149 mg/dL and 138 mg/dL. Patients with blood sugar level that exceeded 100 mg/dL pre-
incision had shown a 1.7 times greater risk of SSI [30]. 
The strength of this study is its large number of patients (n > 400) and follow-up. The 
reported cases of surgical site infection were not when the patient was in the hospital (in-
patient) but during 30–60 days after the day of surgery when they returned to the outpa-
tient clinic. The limitation of this study is that severe cases in ICU and those who died 
were not accounted for, and there were laboratory limitations, and therefore, the bacteria 
that cause SSI were not identified. 
  




The usage of prophylactic antibiotics for surgical procedures was high and varied 
between hospitals. The low concordance to antibiotic therapeutic guidelines suggested 
injudicious antibiotic use. Further surveillance is needed to identify the incidence of anti-
biotic-resistant bacteria in the future. It is highly recommended that surgeons abide by 
guideline recommendations, using only a single antibiotic dose for clean surgery. Further 
intervention and strategies in implementing antibiotic stewardship are needed to improve 
antibiotic prescribing and its use. 
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